Purpose: To evaluate the role of core antigen (Ortho trak-C assay) as a marker of active HCV infection in comparison to HCV RNA as detected by reverse transcription polymerase chain reaction (RT-PCR). Methods: This evaluation was carried out during January 2000 to December 2003 in HCV infected individuals who were treatment naïve or were on anti-viral therapy. Additionally, sequential plasma samples from patients on clinical follow-up were included in this study. A total of 167 samples from 61 patients were tested by trak-C and RT-PCR. HCV RNA detection was achieved by a RT PCR. Trak-C assay results were also compared in a limited proportion of these samples with known HCV viral load and genotype. Results: Of 167 samples tested, 56.9% were RNA positive and 43.1% were RNA negative while 50.3% were trak-C positive and 49.7% were trak-C negative, yielding a sensitivity of 85.3% and a specificity of 95.8% for the trak-C assay (Kappa co-efficient = 0.8). The concentration of HCVcAg and HCV RNA showed significant correlation (n=38, r=0.334, P=0.04). The trak-C assay detected the most prevalent HCV genotypes in India without significant difference (P=0.335). The difference between mean absorbance values of HCV RNA positive samples compared to HCV RNA negative samples in the trak-C assay was highly significant (P<0.000). Qualitative results of trak-C assay and RT-PCR were comparable in 93% of follow-up samples. Conclusions: Trak-C assay can be recommended for confirmation of HCV infection and follow-up in laboratories with resource-poor facilities.
population. About 20 million people in India alone are infected suggest that the improved assay with the immune-complex as estimated by a reported HCV antibody (HCV-Ab) prevalence dissociation step can be used for diagnosis of acute HCV of 1.8%.
1 Screening of blood donations, achieved mainly by infection, 5 for assessing chronic infection with HCV 6 and to serological identification of HCV-Ab, has largely reduced monitor response to anti-viral therapy. 7 In this study we have transmission of HCV.
2 However, antibody detection is not a evaluated a new commercially available enzyme-linked reliable marker in the pre-seroconversion phase of infection, immunosorbent assay (trak-C Ortho Clinical Diagnostics, Inc. for monitoring individuals on anti-viral therapy or for Raritan, New Jersey) for the detection and quantitation of HCV assessing stage of infection. Additionally HCV-Ab is not a core antigen (HCVcAg) in plasma/serum samples in the useful marker for individuals on immunosuppressive therapy presence/absence of HCV-Ab. It was also attempted to or in those with impaired immunity. To overcome these determine the utility of this assay for assessing virological shortfalls of antibody screening for HCV, a sensitive and response in patients on anti-viral therapy. specific assay such as reverse transcription polymerase chain reaction (RT-PCR) to detect HCV RNA has been the Materials and Methods recommendation till-date. This procedure however requires Clinical samples -Recent reports technical expertise, dedicated laboratory space, is time consuming even with automation and is expensive. Therefore, there is a need to develop newer assays, which are costeffective, sensitive and easy to perform and can reduce the serological window period to identify HCV viraemia. The HCV core antigen testing to screen individuals, who were negative for HCV-Ab 1 was first described in 1996. 3 This was further improved in 1999 with the addition of an immune-complex One hundred and sixty seven samples were included from 61 patients whose sequential samples were available in the clinical virology laboratory at the Christian Medical College, Vellore. As part of clinical investigations these samples were sent to the laboratory for HCV RNA detection, during the period January 2000 to December 2003. The patients were referred from the Gastroenterology and Nephrology units of this tertiary care center, comprising treatment naïve individuals and those on anti-viral therapy. Among this study group, fifteen patients had provided samples before, after and while on anti-viral therapy. Blood samples were collected after verbal consent in EDTA containing tubes and separated plasma was stored in aliquots at -60 trak-C assays were done on separate aliquots of the same sample. Antibody confirmation and RNA quantitation was done on samples for which additional aliquots were available.
Antibody screening and confirmation
Detection of HCV-Ab was done using a third generation enzyme-linked immunosorbent assay (ELISA) (UBI HCV EIA 4.0, United Biomedical Inc. USA) and/or by AXSYM (HCV version 3.0, Abbott Laboratories, Illinois). Results were calculated based on the cut-off absorbance value calculated for each ELISA run. All samples above the cut-off absorbance value were considered positive by ELISA. The signal: cut-off ratio (S/CO) was automatically calculated by the AXSYM.
antigen was calculated in pg/mL by a standard graph with the absorbance values of the standards provided by the manufacturer. The concentration of standards ranging from 0 pg/mL to 100 pg/mL. All the samples were tested in singleton and results interpreted following the manufacturer's instructions, samples were considered positive when the concentration of total core antigen was ≥ 1.5 pg/mL
Statistical analysis
Statistical analysis was performed using the statistical packages Epi info (version 6.04b) Table. The degree of agreement shown between RT-PCR and core antigen for HCV detection A qualitative nucleic acid testing was performed on all the as indicated by the kappa coefficient was 0.8. samples. RNA was obtained using the Qiagen extraction protocol (QIAamp Viral RNA Mini kit, Qiagen, Germany) and Of the 61 patients studied, 49 were RNA positive and 12 a sensitive in-house nested RT-PCR standardized in this were RNA negative. In 34 of the 49 patients who were initially laboratory 8 using primers specific for the 5´ noncoding region RNA positive, RNA status varied in the sequential samples of the HCV genome was employed. 9 drawn from these patients, while 15 patients were consistently RNA positive. Eight of the 12 RNA negative patients were also On samples (n=38) that had additional aliquots, HCV RNA negative for HCV-Ab. quantitation was done using a commercial assay (Amplicor HCV MONITOR version 2.0, Roche Diagnostics, New Jersey, Eleven of the 14 RNA positive, trak-C negative samples were tested using RIBA. Seven out of eleven were positive for all the antigens. Three out of the remaining four samples Genotyping was done on 22(36%) samples by a type were positive for c100(p), 5-1-1(p), c33c c22(p). The remaining specific PCR method as standardized in this laboratory. 10 samples were positive for all the antigens but showed a band HCV core antigen assay against human superoxide dismutase (hSOD) and were hence deemed indeterminate. Plasma samples were tested for the total core antigen using the trak-C assay according to the manufacturer's instruction.
A total of 38 samples were quantitated for HCV RNA in USA).
The sample was treated with 100 µL of pretreatment buffer and kept in a 56 o C water bath for complete dissociation of the HCV core antigen-antibody complex. Hundred microlitres of the pre treated sample and control samples were mixed with 100 µL of the reaction buffer and incubated at room temperature (RT) in the wells coated with HCVcAg specific monoclonal antibody with agitation. The plates were washed and incubated for 30 minutes at RT with 200 µL of conjugate. Plates were washed again and incubated at RT with 200 µL of substrate. After the addition of 50 µL of stop solution the optical density of the samples, controls and the standards were read in an ELISA reader (µ-quant, Bio-Tek instruments, USA) at 490 nm using 620 nm as the reference wavelength. The concentration of core IU/mL and compared with HCVcAg levels in pg/mL as shown www.ijmm.org in a scatter plot in Fig. 1. HCV genotype of the 22 (36%) patients was as follows: genotype 3 (n=13), followed by genotype 1 (n=7) and genotype 4 (n=2), these 22 patients were trak-C positive. The trak-C assay detected the most prevalent Indian genotypes without significant difference (P=0.335).
The mean absorbance value of HCV RNA positive samples in trak-C assay was significantly higher than the mean absorbance value of HCV RNA negative samples (P<0.000) (Fig. 2) .
The core antigen levels of the fifteen patients (A-O) for while on therapy and increased after therapy for nonresponders. We have tried to correlate core antigen levels on a group of patients (n=15) on anti-viral therapy (Fig. 3 ).
These 15 patients had given blood samples at three different time points: before, after and while on anti-viral therapy. HCVcAg titers and HCV RNA (not shown) are compared in Fig. 3 . Of these 15 patients, three patients (patient No. F, B and C) showed discordance between HCVcAg and HCV RNA results at one of the three time points. Patient number 'F' was positive for HCVcAg while on therapy while HCV RNA was negative. However, after therapy both HCVcAg and HCV RNA were positive suggesting that this patient is a non-responder. Of the two remaining samples, patient no. B whom samples were available before, after and during anti viral therapy are shown in Fig. 3 . Core antigen levels dropped was HCV RNA positive after therapy while HCVcAg was negative, while the other patient no. C was negative for HCVcAg while on therapy while HCV RNA was positive. However, the subsequent sample (after therapy) from patient C was negative for HCVcAg and HCV RNA.
Discussion
HCV RNA is the gold standard for detection of HCV infection. New molecular techniques to detect and quantify HCV RNA are available and many studies have tried to establish a relationship between viral load, disease severity and progression of the disease. Further, in order to reduce the residual risk of HCV transmission through blood banks it was made mandatory for European Blood banks in January 2, 2002 to test every blood and plasma donation for either HCVcAg or HCV RNA. 11 In previously reported studies, HCVcAg was detected one day later than HCV RNA in patients undergoing seroconversion but the sensitivity of this assay did not match the sensitivity shown by a single donor nucleic acid testing (NAT) in detecting early HCV infection. 12, 13 However, HCV ( w w w The box represents the middle 50% of the data or the interquartile range (IQR) (25 th to 75 th percentile). The horizontal line within each box represents the median. The upper adjacent value is the largest observation that is less than or equal to the 75 th percentile plus 1.5 times IQR. The lower adjacent value is the smallest observation that is greater than or equal to the 25 th percentile minus 1.5 times IQR. The adjacent values are displayed as T-shaped lines that extend vertically from each end of the box. Outliers are shown as black circles. RNA detection for single donations is not a feasible option because of the exorbitant cost, infrastructure and requirement of specially trained personnel. But many developed countries have introduced NAT in their blood banks using the pool testing method to reduce costs. However, pooling of samples reduces the sensitivity of the assay compared to single donor NAT. Hence core antigen is considered an alternative to NAT because single donations can be tested; it is less expensive and does not require specific infrastructure and trained personnel. Trak-C is an improvement on the core antigen assay because it is suitable to test antibody positive and antibody negative samples. The superior sensitivity of the trak-C may be attributed to the dissociation step and the new conjugate used in this assay.
approximately 10 4 IU/mL, which is in agreement with earlier published studies. It is noteworthy that 12 of these 14 samples missed by trak-C (Table) were from patients on anti-viral therapy.
Of the 14 samples deemed negative by trak-C (Table) RIBA results were available for 11 samples. All the samples showed 4+ reactivity to the core antigen and other antigens as well. It is possible that this robust antibody response in these patients contributed to the lack of dissociation of antigenantibody complexes in the pre-treatment step thereby leading to false negative results. Alternatively it may be speculated that incomplete HCV viral core particles, may lack the necessary antigenic site needed for binding with monoclonal antibody that is coated on the wells of the trak-C assay hence rendering Our study demonstrates that HCV RNA status correlates them negative in this assay. It is known that even in other with the HCV core protein profile in chronically infected viral infections such as that with hepatitis B virus, nucleic acid individuals (Kappa = 0.8). The significantly higher absorbance concentration as determined by PCR does not correlate with values of trak-C in RNA positive samples corroborate this the viral antigen concentration in the peripheral blood observation (Fig. 2) . The assay exhibited a sensitivity of 85.3% circulation. 20 and a specificity of 95.8% as compared to HCV RNA detection, which is lower, compared to earlier studies, which show 100% Forty-two out of 45 (93.0%) samples, from patient on specificity. 14, 15 This may be due to heterogeneity of the study follow-up, showed good correlation on qualitative results of patients with regard to risk factors and treatment status. Of HCVcAg and HCV RNA tests. Hence our study using the trak the 61 patients in this study with sequential samples, 45 (74%) C assay on a limited population of patients on anti-viral patients showed consistent results as compared to HCV RNA therapy seems to predict response in a manner similar to other result and 16 patients showed discordant results compared studies. 18 to HCV RNA. Of these 16 patients, 15 were on anti-viral Trak-C is a simple and reliable direct method for detection therapy, suggesting that the discrepancy could be due to anti-of HCV infection. Since this assay is based on ELISA viral therapy. Fifteen of these sixteen patients were however technology, it can be easily performed in most laboratories and concordant for at least one of the sequential sample drawn is cost-effective. Further it does not need any specially trained from these patient. One patient was consistently negative by personnel, special equipment or infrastructure except that trak-C for all follow-up samples while RNA was positive.
which is required for ELISA tests. It also reduces the problems There have been a few studies, which have tried to of possible cross contamination and false positives as in a correlate core antigen levels with HCV viral loads. Bouvier-nested PCR protocol. Hence it is a suitable alternative to HCV Alias et al reported that one pg/mL is approximately equal to RNA detection. HCVcAg is also more stable as compared to
Other studies including those involving RNA, the latter more likely to be degraded by the RNAase in chronically infected individuals have reported that the lower the blood sample. It would also serve as a good direct HCV limit of detection of trak-C corresponds to viral RNA titers of detection method in patients who are immunosuppressed. IU/mL. 17, 18 In the present study, we have attempted to Further this assay could be employed during preevaluate the relationship between HCVcAg concentration and seroconversion period when the antibody assays are negative. HCV RNA loads. A total of 38 samples from this study panel During the pre-seroconversion period the viral load is in the 8,000 IU/mL. were compared. The HCV core antigen concentration correlated significantly with HCV RNA titer (r=0.334, P=0.04). However, it is known that the correlation between HCV RNA and core antigen levels may vary between patients. 19 The observation of high virus load (10 6 ) and low core antigen levels in five patients (Fig. 1 ) may be the result of ongoing anti-viral therapy in these patients.
Quantitation was performed on 11 of the 14 HCV RNA positive samples, which were negative by trak-C. Eight out of fourteen samples were below 10 4 IU/mL, two samples were 10 5 IU/mL and one was 10 6 IU/mL of plasma. Our data therefore suggests that the lower detection limit of core antigen is range of 10 6 to 10 8 IU/mL wherein the trak-C could be expected to be positive. However, there are individuals who during their pre-seroconversion period may have low viral load (<10 4 ) which will not be detected by this assay. 17, 18 The core antigen assay may thus require further fine tuning prior to its use as a screening assay in blood banks.
The Indian population harbors a plethora of genotypes. 21, 22 A recent study suggests that core antigen levels are not influenced by mutations in the core region and the HCVcAg assay seems to identify genotypes 1-4 with equal sensitivity. 23 Another study among dialysis patients reported significant correlation between HCVcAg and HCV RNA levels across www.ijmm.org ) .
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Daniel et al -Significance of HCV Core Antigen as a HCV Marker different HCV genotypes. 20 Of the 22 samples that were genotyped in this study, all the patients were positive for HCVcAg. There seems to be no discrepancy between genotype and HCVcAg positivity. Even though genotype did not seem to affect the core antigen levels (P=0.335), a larger number of samples from this region need to be tested to understand the relationship between HCVcAg and different HCV variants. This assay presently shows a potential to detect the most prevalent genotypes in India i.e, genotypes 1 and 3.
In summary, this technique provides smaller laboratories with the capacity to detect active HCV infection comparable to RNA detection techniques, thereby improving the monitoring of patients who are infected with HCV. ) .
